#ProstateCancer #MedicalInnovation #Radiopharmaceuticals
markets.businessinsider.com
Lantheus Announces FDA Approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection
New formulation of its widely-used U. S. market-leading PSMA PET imaging agentcombines the
diagnostic performance of PYLARIFY (piflufolastat F 18) with the potential for larger batches and greater patient availability
PYLARIFY TruVu™ is expected to launch in 4Q 2026, with a phased geographic rollout to support a seamless customer transition
BEDFORD, Mass.
#ArtificialIntelligence #Radiology #FutureOfWork
edition.cnn.com
This job has become the ultimate case study for why AI won't replace human workers
Want to understand how artificial intelligence could change your job. Look to radiology as a clue.
Radiology has become a recent talking point in the AI race.
#ArtificialIntelligence #Radiology #HealthcareInnovation
us.cnn.com
This job has become the ultimate case study for why AI won't replace human workers | CNN Business
Want to understand how artificial intelligence could change your job. Look to radiology as a clue.
Radiology has become a recent talking point in the AI race.
#HepatocellularCarcinoma #Radiotherapy #TACE
www.medscape.com
Adding Radiotherapy to TACE May Improve Early HCC Survival
In a comparative study, the early addition of radiotherapy to transarterial chemoembolization (TACE) was associated with improved 5-year overall survival and progression-free survival compared with TACE alone among patients with early-stage hepatocellular carcinoma (HCC).
